In angioplasty procedures, a balloon is fed through a catheter and used to prop open an artery that has become narrowed or blocked. In cases where stenting is appropriate, a stent mounted on a balloon is inserted and inflation of the balloon expands the stent against the blocked artery wall to hold the vessel open. The balloon is then deflated and the catheter is withdrawn. Stent treatment of arteries holds them open and improves blood flow to the heart. In cases where post-dilatation is needed, a high-pressure balloon is inflated inside a stent to help better place the stent against the vessel wall.
ev3 Inc. today announced the completion of patient enrollment in the DURABILITY II trial, a prospective, multi-center, single-arm study evaluating the EverFlex® Self-Expanding Stent System for the treatment of superficial femoral artery (SFA) and proximal popliteal lesions. The DURABILITY II study will support a planned Premarket Approval (PMA) filing with the U.S. Food and Drug Administration to obtain approval of the EverFlex Self-Expanding Stent System for use in the SFA.
A 3-year, retrospective study by cardiologists from the Minneapolis Heart Institute Foundation and the University of Minnesota determined that 28.8% of patients with significant coronary artery disease (CAD) who did not undergo complete revascularization had a higher mortality rate than patients completely revascularized. Results of this study appear in the May issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions.
A 3-year, retrospective study by cardiologists from the Minneapolis Heart Institute Foundation and the University of Minnesota determined that 28.8% of patients with significant coronary artery disease who did not undergo complete revascularization had a higher mortality rate than patients completely revascularized.
Boston Scientific Corporation today announced the launch of its new Kinetix™ Guidewire for use in percutaneous coronary intervention (PCI) procedures. Guidewires are small flexible wires physicians use to deliver interventional devices such as drug-eluting stents. The Kinetix Guidewire features a unique micro-cut nitinol sleeve designed for significantly improved torque control compared to conventional spring coil guidewires.
Moving to expand its product offering, Medtronic, Inc., announced today that it has completed the acquisition of Invatec, a developer of innovative medical technologies for the interventional treatment of cardiovascular disease.
AngioDynamics today announced the first patient treatment and growing enrollment in a pilot study of the use of the Company's NanoKnife® Irreversible Electroporation (IRE) System in the treatment of early stage hepatocellular carcinoma (HCC), or primary liver cancer. This clinical trial is being conducted under the supervision of Professor Jordi Bruix of the Barcelona Clinic Liver Cancer Group of the University of Barcelona and Professor Riccardo Lencioni of the University of Pisa School of Medicine.
Research led by T. Cooper Woods, PhD, Assistant Professor of Pharmacology and Experimental Therapeutics at LSU Health Sciences Center New Orleans, and Director of the Molecular Cardiology Research Laboratory at Ochsner Clinic Foundation, has identified the mechanism of how a drug commonly used on stents to prevent reclosure of coronary arteries, regulates cell movement which is critical to wound healing and the progression of diseases like cancer.
At 56, Tim Obrenski found himself getting so exhausted that he couldn't even pull weeds from his garden. A visit to the cardiologist uncovered a major blockage in his heart's left main artery, and he was told he needed bypass surgery.
According to new results from the 2009 Leapfrog Hospital Survey released today at the World Health Congress in Washington, DC, hospital quality needs significant improvement and waste remains rampant. One encouraging sign: steady improvements over time, supporting the value of hundreds of purchasers' growing efforts to use Leapfrog performance data in decision-making, contracting, pay for performance, and benefits design.
Svelte Medical Systems, Inc. is pleased to announce that it has successfully completed the extension of its Series A financing from institutional and private investors including CNF Investments, Apjohn Ventures and the Fischell family. The company's Series A extension was oversubscribed and included an initial investment by Norwich Ventures LP. Norwich Ventures is a seed and early-stage venture capital firm committed to helping entrepreneurs, healthcare professionals and inventors build innovative medical technology companies.
The Society of Interventional Radiology and Custom Computer Specialists Inc. have entered into an exclusive, long-term licensing agreement to promote innovation and the development of HI-IQ-, the leading information management system for interventional radiology.
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced that the results of the M118 EMINENCE clinical trial have published in Circulation.
Orthopedic surgeons are often hamstrung by less-than-ideal grafting material when performing surgeries for complex bone injuries resulting from trauma, aging or cancer. Conventional synthetic bone grafts are typically made of stiff polymers or brittle ceramics, and cannot readily conform to the complex and irregular shapes that often result from injury; in addition, they often require metallic fixation devices that require open surgeries to insert and remove.
Kenneth "Buddy" Conant hit some clothing stores for a little shopping spree recently, but it wasn't because he'd suddenly become enthralled with the latest fashions. The truth was, he was starting to resemble a kid wearing a grown man's clothes.
While health policy researchers commonly suggest that geographic variations in the amount of medical care provided can be attributed to hospital costs or physician practice patterns, a new study examining regional utilization of a specific surgical procedure - minimally invasive aneurysm repair - shows that is not the case.
Researchers from the Frances Payne Bolton School of Nursing at Case Western Reserve University found that one year after 248 individuals completed a 12-week cardiac rehabilitation program following a heart attack, bypass surgery or angioplasty, only 37% exercised three times a week to keep their hearts healthy.
AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, announced today that the company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its AngioSculpt® PTA Scoring Balloon Catheter for dilatation of lesions in renal arteries.
Celera Corporation today announced the publication of data reporting that elderly (over age 70) carriers of the KIF6 gene variant with prior vascular disease received significant benefit from pravastatin (Pravachol®) therapy. Previous research has shown that a variant of the KIF6 gene, a member of the molecular motor protein kinesin family, is associated with up to a 55% increased risk of primary and recurrent coronary heart disease (CHD) events in the placebo arms of the clinical trials, and that this increased risk is virtually eliminated with statin therapy.
AngioDynamics today welcomed the publication of the book “Irreversible Electroporation,” published by Springer Berlin Heidelberg.
Individuals between 30 and 80 years of age, who have had a transient ischemic attack (TIA) or non-severe stroke within the past 30 days, and who cannot be treated surgically, may be eligible to participate in a Phase III clinical trial of a minimally invasive stenting procedure at the Cedars-Sinai Neurovascular Center. The study will focus specifically on patients who have had an intracranial artery narrowed by at least 70 percent and who are experiencing recurrent strokes or TIAs despite being on anti-clotting medication.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.